Insulin-like growth factors I and II exert pleiotropic effects on diverse cell types. Although current evidence supports a role for IGF-I as a major postnatal growth factor, regulated in part by growth hormone, the functions of IGF-II in growth and development remain undefined. Each IGF interacts initially with a unique high-affinity receptor located in the plasma membrane of responsive cells. Many of the actions of both peptides are mediated by the IGF-I receptor, a ligand-activated tyrosine-specific protein kinase structurally related to the insulin receptor. By contrast the role of the IGF-II receptor in IGF signaling is unclear, despite its apparent identity with the cation-independent mannose-6phosphate receptor involved in targeting lysosomal enzymes. As an additional complexity actions of both IGFs in target tissues may be modified by interaction with various locally-secreted binding proteins. As part of a long-term goal to define the mechanisms by which the actions of the IGFs are integrated within the cell, the focus of this application will be on the functions and regulation of IGF-II, the IGF-II receptor, and a novel IGF binding protein in a model cell system, the differentiating myoblast. Toward this end the following four specific aims are proposed: 1.To determine the role of IGF-II in muscle differentiation and to define its mechanisms of qlction. 2.To dissect the functions of the IGF-II gene promoter, in order to define and characterize the elements required for induction of gene expression during myoblast differentiation. 3.To define the function of the IGF-II receptor in muscle differentiation and to characterize the mechanisms involved in regulation of receptor gene expression in this model system. 4.To determine the mechanisms of action and the regulation of a novel IGF binding protein whose secretion is induced during myoblast differentiation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK042748-03
Application #
3243933
Study Section
Endocrinology Study Section (END)
Project Start
1991-01-01
Project End
1993-12-31
Budget Start
1993-01-29
Budget End
1993-12-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Washington University
Department
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Rotwein, Peter (2018) The insulin-like growth factor 2 gene and locus in nonmammalian vertebrates: Organizational simplicity with duplication but limited divergence in fish. J Biol Chem 293:15912-15932
Rotwein, Peter (2018) The complex genetics of human insulin-like growth factor 2 are not reflected in public databases. J Biol Chem 293:4324-4333
Rotwein, Peter (2017) Large-scale analysis of variation in the insulin-like growth factor family in humans reveals rare disease links and common polymorphisms. J Biol Chem 292:9252-9261
Gross, Sean M; Rotwein, Peter (2016) Mapping growth-factor-modulated Akt signaling dynamics. J Cell Sci 129:2052-63
Gross, Sean M; Rotwein, Peter (2016) Unraveling Growth Factor Signaling and Cell Cycle Progression in Individual Fibroblasts. J Biol Chem 291:14628-38
Alzhanov, Damir; Rotwein, Peter (2016) Characterizing a distal muscle enhancer in the mouse Igf2 locus. Physiol Genomics 48:167-72
Gardner, Samantha; Gross, Sean M; David, Larry L et al. (2015) Separating myoblast differentiation from muscle cell fusion using IGF-I and the p38 MAP kinase inhibitor SB202190. Am J Physiol Cell Physiol 309:C491-500
Rotwein, Peter S (2015) Editorial: is it time for an evolutionarily based human endocrinology? Mol Endocrinol 29:487-9
Gross, Sean M; Rotwein, Peter (2015) Akt signaling dynamics in individual cells. J Cell Sci 128:2509-19
Rotwein, Peter (2014) Editorial: the fall of mechanogrowth factor? Mol Endocrinol 28:155-6

Showing the most recent 10 out of 63 publications